ReviewThe Lancet regional health. Western Pacific2025
Extranodal NK/T-cell lymphoma: an update of the molecular characterization of the tumor and microenvironment, and its clinical implications.
Review in The Lancet regional health. Western Pacific, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Current status and progress in the diagnosis and treatment of monomorphic epitheliotropic intestinal T-cell lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Pooled it
- Article
- An epigenetic Achilles' heel in extranodal NK/T-cell lymphoma?Haematologica · 2026Article
- Focus on extranodal NK/T cell lymphomas.Leukemia · 2026Article
- Article
- Review
- Selinexor plus tislelizumab in patients with relapsed/refractory natural killer/T-cell lymphoma after failure of PD-1 blockade: the phase 1b TOUCH trial.The oncologist · 2026Article
- Integrating ANP32A expression with Ann Arbor stage refines prognostic stratification in extranodal NK/T-cell lymphoma.Diagnostic pathology · 2026Article
- Review
- Molecular pathogenesis and evolving treatment landscape of extranodal NK/T-cell lymphoma.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2026Review
- Extranodal nasal-orbital communicating lesions NK/T cell lymphoma with ocular symptoms as the initial manifestation misdiagnosed as sinusitis and orbital cellulitis: a case report and literature review.Frontiers in oncology · 2026Article
- Epstein-Barr Virus-Associated T/NK-Cell Neoplasms.Journal of medical virology · 2026Review
- An Unforeseen Diagnosis After Liver Transplantation for Acute Liver Failure: Extranodal NK/T-Cell Lymphoma.Case reports in hepatology · 2026Article
- Frequent Novel Viral Focal Copy Number Gains Potentiate Radiosensitivity in Natural Killer/T-Cell Lymphoma.Cancer communications (London, England) · 2026Article
- Beyond monotherapy: multimodal strategies integrating immune checkpoint inhibitors in lymphoma management.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extranodal NK/T-cell lymphoma (ENKTL) is an aggressive lymphoma associated with Epstein-Barr virus which does not respond to conventional anthracycline-based chemotherapy. Recent multi-omics studies have identified genetic and epigenetic alterations involved in the tumor pathogenesis and enabled the characterisation of distinct molecular subtypes with therapeutic and prognostic implications. Similarly, genomic and transcriptomic studies have shed new light on the tumor microenvironment (TME) and potential interactions with the EBV-infected malignant cells, as well as their potential influence on tumor development and progression. This review provides an update on the key genetic alterations and analysis of the recurrent mutations of ENKTL, the role of EBV, epigenetic modifications and emerging molecular classifications of both the tumor and the TME. We also explore the prognostic and therapeutic applications of these new insights, and how they are beginning to reshape the current understanding and future clinical management of this difficult-to-treat disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.